The treatment landscape for advanced/metastatic renal cell carcinoma includes well-established angiogenesis and mTOR inhibitors, many of which have broad labels allowing their use across several treatment settings. The approval of the first PD-1 inhibitor in this indication, Opdivo, has begun to have a significant impact on the treatment algorithm, particularly in later-line disease settings.
- Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (EU5)
Author(s): Evrim Gurpinar
Evrim Gurpinar, Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group.
Prior to joining DRG, Evrim was a Postdoctoral Fellow at the Cancer Research UK Beatson Institute, where he studied the effects of p53 tumor suppressor mutations on cancer cell metabolism. He received his B.S. in Cell and Molecular Biology from Tulane University as a Fulbright Scholar and his Ph.D. from the University of Alabama at Birmingham School of Medicine. His PhD work entailed a preclinical drug development project to identify novel drug candidates for non-small cell lung cancer.